Real Solutions Price controls will slow drug innovation
Navigating the regulatory regimen is “hugely expensive,” said Ian Adams, Sacramento director of the R Street Institute, a right-of-center think tank. This is “some of the most sophisticated science going on in the world” and researchers don’t know if any investment will pay off.
